Advanced search
Publication Cover
Hematology Volume 26, 2021 - Issue 1
Submit an article Journal homepage
3,347
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of FLT3-ITD-positive AML treated with gilteritinib

Takeshi Kondoa Blood Disorders Center, Aiiku Hospital, Sapporo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7455-5824
ORCID Icon,
Masahiro Onozawab Department of Hematology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
,
Shinichi Fujisawac Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan
,
Shinpei Haradaa Blood Disorders Center, Aiiku Hospital, Sapporo, Japan
,
Reiki Ogasawaraa Blood Disorders Center, Aiiku Hospital, Sapporo, JapanORCID Iconhttps://orcid.org/0000-0002-1136-5035
ORCID Icon,
Koh Izumiyamaa Blood Disorders Center, Aiiku Hospital, Sapporo, Japan
,
Makoto Saitoa Blood Disorders Center, Aiiku Hospital, Sapporo, Japan
,
Masanobu Moriokaa Blood Disorders Center, Aiiku Hospital, Sapporo, Japan
,
Akio Moria Blood Disorders Center, Aiiku Hospital, Sapporo, Japan
&
Takanori Teshimab Department of Hematology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan;c Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan
 show all
Pages 256-260 | Published online: 25 Feb 2021

References

  • Daver N, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299–312.
  • Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017;18:1061–1075.
  • Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381:1728–1740.
  • McMahon CM, Canaani J, Rea B, et al. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Adv. 2019;3:1581–1585.
  • DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood 2020; 135: 85–96.
  • Sakaguchi M, Nakajima N, Yamaguchi H, et al. The sensitivity of the FLT3-ITD detection method is an important consideration when diagnosing acute myeloid leukemia. Leuk Res Rep. 2020;13:100198.
  • Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia. 1995;9:10–14.
  • Huls G, Chitu DA, Havelange V, et al. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood. 2019;133:1457–1464.
  • Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244–3254.
  • Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients. Cancer. 1985;55:1633–1636.
  • Montesinos P, Sanz MA. The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature. Mediterr J Hematol Infect Dis. 2011;3:e2011059.
  • Sakaguchi M, Yamaguchi H, Najima Y, et al. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood Adv. 2018;2:2744–2754.
  • Kottaridis PD, Gale RE, Langabeer SE, et al. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood. 2002;100:2393–2398.
  • Shih LY, Huang CF, Wu JH, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood. 2002;100:2387–2392.
  • Wakita S, Yamaguchi H, Omori I, et al. Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. Leukemia. 2013;27:1044–1052.
  • Yun HD, Nathan S, Larson M, et al. Erythroid differentiation of myeloblast induced by gilteritinib in relapsed. FLT3-ITD–positive acute myeloid leukemia. Blood Adv. 2019;3:3709–3712.
  • Sexauer A, Perl A, Yang X, et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood. 2012;120:4205–4214.
  • Nybakken GE, Canaani J, Roy D, et al. Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone. Leukemia. 2016;30:1422–1425.
  • Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481:506–510.
  • Levis M, Shi W, Chang K, et al. FLT3 inhibitors added to induction therapy induce deeper remissions. Blood. 2020;135:75–78.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.